A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 28 May 2019 Planned End Date changed from 1 Mar 2020 to 1 Jul 2020.
- 28 May 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2020.
- 07 Jun 2018 This trial has been completed in Poland.